Scott Davies Sells 615 Shares of Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) insider Scott Davies sold 615 shares of the company’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $200.00, for a total value of $123,000.00. Following the completion of the sale, the insider owned 20,338 shares of the company’s stock, valued at $4,067,600. This trade represents a 2.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Stock Performance

NASDAQ:ILMN opened at $203.01 on Wednesday. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $207.00. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The firm has a market capitalization of $30.65 billion, a PE ratio of 37.87, a P/E/G ratio of 2.79 and a beta of 1.45. The stock has a 50-day simple moving average of $178.93 and a two-hundred day simple moving average of $148.02.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the previous year, the company posted $1.19 EPS. The firm’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Analysts forecast that Illumina, Inc. will post 5.36 EPS for the current year.

Institutional Trading of Illumina

Institutional investors have recently bought and sold shares of the stock. Elyxium Wealth LLC bought a new position in Illumina during the 4th quarter valued at about $25,000. Creative Capital Management Investments LLC grew its stake in shares of Illumina by 160.0% during the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after buying an additional 120 shares during the last quarter. TD Waterhouse Canada Inc. purchased a new stake in shares of Illumina in the fourth quarter worth approximately $26,000. Laurel Wealth Advisors LLC bought a new stake in shares of Illumina during the 4th quarter worth approximately $26,000. Finally, Elevation Wealth Partners LLC boosted its holdings in Illumina by 52.5% during the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after acquiring an additional 84 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Clinical sequencing and NovaSeq X demand support growth. Illumina’s second-quarter revenue rose 9.4% year over year to approximately $1.16 billion, beating the $1.13 billion consensus estimate. Management cited clinical momentum and NovaSeq X placements when raising its 2026 revenue forecast to $4.60 billion-$4.64 billion. Illumina Q2 2026 Earnings Call Transcript
• Positive Sentiment: Analysts raised their targets. Piper Sandler reaffirmed its “overweight” rating and increased its price target to $225 from $200. Other recent target increases included $210 and $230, suggesting some analysts expect further upside as sequencing demand improves. Piper Sandler rating update Illumina price target raised to $210 Illumina price target raised to $230
• Neutral Sentiment: Strong momentum has pushed the stock near a 52-week high. The rally reflects improving revenue expectations and earnings execution, but the elevated share price could make ILMN more sensitive to any weakness in guidance, instrument placements or clinical adoption. Illumina hits a fresh high
• Negative Sentiment: Valuation concerns may limit additional gains. With the shares trading at elevated earnings and growth multiples, some analysis suggests Illumina may be overvalued despite improving fundamentals. Investors may demand continued strong execution to justify the current valuation. Cash-producing stocks analysis
• Negative Sentiment: An executive sold a modest amount of stock. Chief Legal Officer Scott M. Davies sold 615 shares for approximately $123,000, reducing his holdings by 2.94%. Because the transaction occurred under a pre-arranged Rule 10b5-1 plan and he retained 20,338 shares, the signal is limited but slightly negative for sentiment. Illumina insider sale

Analyst Ratings Changes

A number of research firms have recently weighed in on ILMN. Evercore reaffirmed an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. Leerink Partners boosted their price target on Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a report on Friday, July 17th. Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective for the company in a report on Thursday, May 14th. Finally, Guggenheim lifted their price objective on shares of Illumina from $200.00 to $226.00 and gave the company a “buy” rating in a research report on Friday. Eight equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $188.40.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.